AU3469400A - Pharmaceutical compositions for treatment of diseased tissues - Google Patents

Pharmaceutical compositions for treatment of diseased tissues

Info

Publication number
AU3469400A
AU3469400A AU34694/00A AU3469400A AU3469400A AU 3469400 A AU3469400 A AU 3469400A AU 34694/00 A AU34694/00 A AU 34694/00A AU 3469400 A AU3469400 A AU 3469400A AU 3469400 A AU3469400 A AU 3469400A
Authority
AU
Australia
Prior art keywords
treatment
pharmaceutical compositions
diseased tissues
diseased
tissues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU34694/00A
Inventor
Clarence C. Lee
Feng-Min Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FENG MIN LEE
Original Assignee
FENG MIN LEE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FENG MIN LEE filed Critical FENG MIN LEE
Publication of AU3469400A publication Critical patent/AU3469400A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU34694/00A 1999-01-05 2000-01-05 Pharmaceutical compositions for treatment of diseased tissues Abandoned AU3469400A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11490699P 1999-01-05 1999-01-05
US60114906 1999-01-05
PCT/US2000/000191 WO2000040269A2 (en) 1999-01-05 2000-01-05 Pharmaceutical compositions for treatment of diseased tissues

Publications (1)

Publication Number Publication Date
AU3469400A true AU3469400A (en) 2000-07-24

Family

ID=22358161

Family Applications (1)

Application Number Title Priority Date Filing Date
AU34694/00A Abandoned AU3469400A (en) 1999-01-05 2000-01-05 Pharmaceutical compositions for treatment of diseased tissues

Country Status (2)

Country Link
AU (1) AU3469400A (en)
WO (1) WO2000040269A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6589940B1 (en) 1997-06-06 2003-07-08 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
DE19957342A1 (en) * 1999-11-29 2001-05-31 Gruenenthal Gmbh Treatment of interleukin (IL)-12 mediated illnesses comprises simultaneous administration of thalidomide or analogue and antiinflammatory cytokine
WO2002069929A1 (en) * 2001-03-06 2002-09-12 Udo Dunzendorfer Trifunctional systems for chronic illnesses
US20020128258A1 (en) * 2001-03-09 2002-09-12 Jean-Pierre Robin Therapeutical method involving subcutaneous administration of drugs containing cephalotaxine derivatives
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
US6982253B2 (en) 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
JP4903997B2 (en) * 2002-07-02 2012-03-28 サザン リサーチ インスティチュート Inhibitors of FtsZ and uses thereof
EP1585548B1 (en) * 2002-12-09 2018-06-27 Abraxis BioScience, LLC Compositions and methods of delivery of pharmacological agents
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
HUE042678T2 (en) 2005-08-31 2019-07-29 Abraxis Bioscience Llc Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
WO2007100382A2 (en) 2005-10-27 2007-09-07 Bernstein Lawrence R Orally administrable gallium compositions and method of use
WO2008058210A2 (en) 2006-11-09 2008-05-15 Bernstein Lawrence R Local administration of gallium compositions to treat pain
KR100923884B1 (en) * 2007-12-11 2009-10-28 주식회사 알앤엘바이오 Method for Preparing Alnus japonica Bark or Stem Extracts Having High Anti-Influenza Viral activity
CN102070481A (en) * 2009-06-11 2011-05-25 辽宁利锋科技开发有限公司 Medicine tromantadine with adamantane structure, anti-tumor application of derivates and analogs thereof having new indications
CN108635367B (en) 2011-08-30 2020-08-21 阿斯泰克斯制药公司 Decitabine derivative formulations
RU2712635C1 (en) * 2014-02-05 2020-01-30 Репонекс Фармасьютикалз А/С Compositions for promoting healing of skin ulcers and wounds
US9592188B2 (en) 2014-05-22 2017-03-14 Yansong Liu Method of treating or reducing the severity of dermatological conditions
PL3049430T3 (en) 2014-07-16 2019-06-28 Depofarma S.P.A. Parietal fraction of propionibacterium granulosum having immunomodulating action
EP3848047A1 (en) 2014-07-24 2021-07-14 Reponex Pharmaceuticals APS Compositions comprising granulocyte-macrophage colony-stimulating factor for the treatment of inflammatory bowel disease
EP3177315B1 (en) * 2014-08-07 2020-10-07 Reponex Pharmaceuticals A/S Compositions for the treatment of peritonitis
JP6768722B2 (en) 2015-07-02 2020-10-14 大塚製薬株式会社 Lyophilized pharmaceutical composition
EP3661522A2 (en) 2017-08-03 2020-06-10 Otsuka Pharmaceutical Co., Ltd. Drug compound and purification methods thereof
NL2031966B1 (en) * 2022-05-23 2023-11-28 Pleco Therapeutics B V Chelating agents for use in cancer therapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476659A (en) * 1982-11-09 1995-12-19 The Scripps Research Institute Cancerous B cell treatment using substituted nucleoside derivatives
US5162111A (en) * 1986-07-30 1992-11-10 Grabstein Kenneth H Treatment of bacterial diseases with granulocyte-macrophage colony stimulating factor

Also Published As

Publication number Publication date
WO2000040269A2 (en) 2000-07-13
WO2000040269A3 (en) 2000-11-30

Similar Documents

Publication Publication Date Title
AU3469400A (en) Pharmaceutical compositions for treatment of diseased tissues
AU1807401A (en) Compositions and methods for therapy and diagnosis of breast cancer
AU2001247615A1 (en) Intracorporeal medicaments for photodynamic treatment of disease
IL147217A0 (en) New spirooxindole derivatives and pharmaceutical compositions containing the same for treatment of pain
AU2435801A (en) Enhanced visualization of medical implants
AU2003200731A1 (en) Compositions and methods for the treatment of tumor
AU2003200740A1 (en) Compositions and methods for the treatment of tumor
AU2495200A (en) Compositions and methods for the treatment of tumor
HUP0201187A3 (en) Use of ecteinascidin743 for producing pharmaceutical compositions suitable for treating cancer
AU2000274383A1 (en) Preparation for treating diseases of bone tissues
AU2002248319A1 (en) Pharmaceutical composition for the prevention and treatment of scar tissue
AUPP968699A0 (en) Therapeutic compositions and method for their preparation
AU7731700A (en) Low dose ifn-gamma for treatment of disease
HUP0104963A3 (en) Compositions for the treatment of skin diseases
AUPQ474599A0 (en) Endoscope for surgical treatment of haemorrhoids
AU2670600A (en) Pharmaceutical composition containing desoxypeganine for the treatment of nicotine dependence
AU1878201A (en) Composition for the treatment of damaged tissue
AU5638400A (en) Compositions and methods for the therapy and diagnosis of breast cancer
AU1953701A (en) Methods and compositions for treatment of inflammatory disease
AU2002253785A1 (en) Catheter and implants for the delivery of therapeutic agents to tissues
AU1022501A (en) Use of compositions for the caring treatment of the skin
AU1405001A (en) Treatment of diseases
HUP0200311A3 (en) Use of aroyl- or arylalkanoylpyridazines for preparation of pharmaceutical compositions
AU2683500A (en) Compositions for the treatment of pain
AU4034800A (en) Novel compositions and methods for prevention and treatment of protozoal disease

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase